Evidence map›Paper›PMID 32751658›Full record

ReviewCells2020

The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders.

Stefano Menini, Carla Iacobini, Martina Vitale, Giuseppe Pugliese

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Metabolic Disorders and Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Stefano MeniniDepartment of Clinical and Molecular Medicine, "La Sapienza" University, 00189 Rome, Italy.ORCID 0000-0001-7328-2385
Carla IacobiniDepartment of Clinical and Molecular Medicine, "La Sapienza" University, 00189 Rome, Italy.
Martina VitaleDepartment of Clinical and Molecular Medicine, "La Sapienza" University, 00189 Rome, Italy.ORCID 0000-0003-4856-7279
Giuseppe PuglieseDepartment of Clinical and Molecular Medicine, "La Sapienza" University, 00189 Rome, Italy.ORCID 0000-0003-1574-0397
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) ranks seventh as a cause of death worldwide. Chronic complications, including cardiovascular, renal, and eye disease, as well as DM-associated non-alcoholic fatty liver disease (NAFLD) account for most of the morbidity and premature mortality in DM. Despite continuous improvements in the management of late complications of DM, significant gaps remain. Therefore, searching for additional strategies to prevent these serious DM-related conditions is of the utmost importance. DM is characterized by a state of low-grade chronic inflammation, which is critical in the progression of complications. Recent clinical trials indicate that targeting the prototypic pro-inflammatory cytokine interleukin-1β (IL-1 β) improves the outcomes of cardiovascular disease, which is the first cause of death in DM patients. Together with IL-18, IL-1β is processed and secreted by the inflammasomes, a class of multiprotein complexes that coordinate inflammatory responses. Several DM-related metabolic factors, including reactive oxygen species, glyco/lipoxidation end products, and cholesterol crystals, have been involved in the pathogenesis of diabetic kidney disease, and diabetic retinopathy, and in the promoting effect of DM on the onset and progression of atherosclerosis and NAFLD. These metabolic factors are also well-established danger signals capable of regulating inflammasome activity. In addition to presenting the current state of knowledge, this review discusses how the mechanistic understanding of inflammasome regulation by metabolic danger signals may hopefully lead to novel therapeutic strategies targeting inflammation for a more effective treatment of diabetic complications.

Indexed as

AnimalsChronic DiseaseDiabetic NephropathiesDiabetic NeuropathiesDiabetic RetinopathyHumansInflammasomesInflammationInterleukin-1betaMetabolic DiseasesNon-alcoholic Fatty Liver DiseaseReactive Oxygen SpeciesSignal TransductionInflammasomesInterleukin-1betaReactive Oxygen Speciescardiovascular diseasediabetic kidney diseasediabetic retinopathyNOD-like receptor pyrin domain-containing-3non-alcoholic fatty liver diseasetoll-like receptors

Identifiers

PMID32751658
PMCPMC7464565
OpenAlexW3046388141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.